Toggle Menu

Press Room

Call to over-rule drug refusal

07/04/2008

A judge has asked an NHS panel to reconsider its decision to refuse a powerful cancer drug to a woman who is the sole carer of her seriously ill husband.

Kidney Cancer Vaccine Shows No Boost in Survival

07/03/2008

The new vaccine vitespen didn't increase recurrence-free survival among kidney cancer patients who'd had surgery, say U.S. researchers.

Fundraiser for Ike student draws almost 3,000 supporters

07/03/2008

Nearly 3,000 people came to Eisenhower for the June 23 dinner and auction to show their support for the Shelby Township 17-year-old who is currently undergoing treatment for an aggressive form of renal cell carcinoma.

Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma

07/02/2008

The results seen with talactoferrin monotherapy in this Phase 2 trial are promising," said Dr. Eric Jonasch, Assistant Professor, MD Anderson Cancer Center, Houston, Texas, and the first author of the study.

Heart failure linked to Sutent treatment

07/02/2008

In a look back at 224 patients treated with sunitinib, researchers found that six (nearly 3 percent) developed signs of heart failure soon after treatment began.

GlaxoSmithKline, Exelixis to end 6-year collaboration

07/01/2008

GSK in December 2007 exercised its development option for XL880, triggering a $35 million milestone payment. The compound, now called GSK089, is in Phase II trials for papillary renal cell carcinoma, gastric cancer and head and neck cancer.

U.S. Rep. Cohen puts emphasis on medical research

07/01/2008

The grant will fund studies of tests for early detection of bladder and kidney cancer.

Results Published in the Journal 'Cancer' Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma

07/01/2008

HOUSTON, July 1 /PRNewswire/ -- Agennix Incorporated today announced the publication of final results from a Phase 2 monotherapy trial with talactoferrin alfa in patients who had failed previous treatment for advanced or metastatic renal cell carcinoma (RCC). Results from the study, which were reported in the July 1 issue of the journal 'Cancer' (volume 113, number 1), demonstrate that talactoferrin is active in RCC, has a favorable toxicity profile, and is a promising candidate for further study in this disease. Source: ImagingEconomics.com

Cytokinetics Announces Clinical Data Regarding Ispinesib in Combination With Capecitabine

06/30/2008

This Phase Ib clinical trial, sponsored by GSK, was an open-label, dose-escalation study of ispinesib in combination with capecitabine on an every 21-day schedule in subjects with advanced solid tumors.

The Future Of Urologic Oncology: Peril And Promise

06/30/2008

Dr. Linehan has been a great example of the surgeon-scientist, as he identified mechanisms that have advanced the treatment of kidney cancer.

Previous  |  1  |  2  |  3  |  4  |  5  |  6  |  7  |  8  |  9  |  10  |  11  |  12  |  13  |  14  |  15  |  16  |  17  |  18  |  19  |  20  |  21  |  22  |  23  |  24  |  25  |  26  |  27  |  28  |  29  |  30  |  31  |  32  |  33  |  34  |  35  |  36  |  37  |  38  |  39  |  40  |  41  |  42  |  43  |  44  |  45  |  46  |  47  |  48  |  49  |  50  |  51  |  52  |  53  |  54  |  55  |  56  |  57  |  58  |  59  |  60  |  61  |  62  |  63  |  64  |  65  |  66  |  67  |  68  |  69  |  70  |  71  |  72  |  73  |  74  |  75  |  76  |  77  |  78  |  79  |  80  |  81  |  82  |  83  |  84  |  85  |  86  |  87  |  88  |  89  |  90  |  91  |  92  |  93  |  94  |  95  |  96  |  97  |  98  |  99  |  100  |  101  |  102  |  103  |  104  |  105  |  106  |  107  |  108  |  109  |  110  |  111  |  112  |  113  |  114  |  115  |  116  |  117  |  118  |  119  |  120  |  121  |  122  |  123  |  124  |  125  |  126  |  127  |  128  |  129  |  130  |  131  |  132  |  133  |  134  |  135  |  136  |  137  |  138  |  139  |  140  |  141  |  142  |  143  |  144  |  145  |  146  |  147  |  148  |  149  |  150  |  151  |  152  |  153  |  154  |  155  |  156  |  157  |  158  |  159  |  160  |  161  |  162  |  163  |  164  |  165  |  166  |  167  |  168  |  169  |  170  |  171  |  172  |  173  |  174  |  175  |  176  |  177  |  178  |  179  |  180  |  181  |  182  |  183  |  184  |  185  |  186  |  187  |  188  |  189  |  190  |  191  |  192  |  193  |  194  |  195  |  196  |  197  |  198  |  199  |  200  |  201  |  202  |  203  |  204  |  205  |  206  |  207  |  208  |  209  |  210  |  211  |  212  |  213  |  214  |  215  |  216  |  217  |  218  |  219  |  220  |  221  |  222  |  223  |  224  |  225  |  226  |  227  |  228  |  229  |  230  |  231  |  232  |  233  |  234  |  235  |  236  |  237  |  238  |  239  |  240  |  241  |  242  |  243  |  244  |  245  |  246  |  247  |  248  |  249  |  250  |  251  |  252  |  253  |  254  |  255  |  256  |  257  |  258  |  259  |  260  |  261  |  262  |  263  |  264  |  265  |  266  |  267  |  268  |  269  |  270  |  271  |  272  |  273  |  274  |  275  |  276  |  277  |  278  |  279  |  280  |  281  |  282  |  283  |  284  |  285  |  286  |  287  |  288  |  289  |  290  |  291  |  292  |  293  |  294  |  295  |  296  |  297  |  298  |  299  |  300  |  301  |  302  |  303  |  304  |  305  |  306  |  307  |  308  |  309  |  310  |  311  |  312  |  313  |  314  |  315  |  316  |  317  |  318  |  319  |  320  |  321  |  322  |  323  |  324  |  325  |  326  |  327  |  328  |  329  |  330  |  331  |  332  |  333  |  334  |  335  |  336  |  337  |  338  |  339  |  340  |  341  |  342  |  343  |  344  |  345  |  346  |  347  |  348  |  349  |  350  |  351  |  352  |  353  |  354  |  355  |  356  |  357  |  358  |  359  |  360  |  361  |  362  |  363  |  364  |  Next
NeonCRM by Neon One